http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2715304-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_577ce3c4a87b295f5e6d09bcf731dd89 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4291 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-42 |
| filingDate | 1994-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a9e00e9f1aa50c297b52f6cb8292954 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7be4d0af1f3cd9cf9b4f39fcf9e368f4 |
| publicationDate | 1995-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | FR-2715304-A1 |
| titleOfInvention | Anti-allergic vaccine. |
| abstract | The present invention relates to a vaccine composition which is useful for treating or preventing type 1 hypersensitivity reactions mediated by immunoglobulins E, inflammatory immune diseases, and for modulating IgE synthesis. The invention also relates to the specific antibodies induced by the immunogenic agent of the vaccine composition, as well as the immunogenic agent used and a method of preparation for obtaining it. The immunogen is an unglycosylated or partially glycosylated polypeptide derived from the Fc fragment of human or primate IgE. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0220038-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0220038-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2330187-A3 |
| priorityDate | 1994-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 242.